Adial Pharmaceuticals Inc (ADIL) Stock Price, Quote & News

Latest News on ADIL

Dec 3, 2024, 8:30 AM EST - 6 weeks ago

Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations

Nov 5, 2024, 8:30 AM EST - 2 months ago

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Sep 19, 2024, 8:30 AM EDT - 4 months ago

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Sep 4, 2024, 9:00 AM EDT - 4 months ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 14, 2024, 8:30 AM EDT - 5 months ago

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 7, 2024, 9:00 AM EDT - 5 months ago

Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jul 31, 2024, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044

Jul 23, 2024, 8:30 AM EDT - 6 months ago

Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Jun 20, 2024, 8:30 AM EDT - 7 months ago

Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder

May 29, 2024, 8:30 AM EDT - 8 months ago

Adial CEO to Present at the Spring MicroCap Rodeo Conference on June 6th

May 15, 2024, 8:30 AM EDT - 8 months ago

Adial Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 22, 2024, 8:30 AM EDT - 9 months ago

Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office

Apr 10, 2024, 2:15 PM EDT - 10 months ago

Adial Pharmaceuticals posts promising update on alcohol disorder drug

Apr 10, 2024, 8:30 AM EDT - 10 months ago

Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder

Apr 2, 2024, 8:30 AM EDT - 10 months ago

Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update

Mar 1, 2024, 7:00 PM EST - 11 months ago

Adial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross Proceeds

Feb 28, 2024, 9:30 AM EST - 11 months ago

Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark Office

Feb 15, 2024, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20

Feb 13, 2024, 9:15 AM EST - 1 year ago

Adial Pharmaceuticals Awarded New Patent Notice of Allowance from the United States Patent and Trademark Office

Jan 18, 2024, 8:30 AM EST - 1 year ago

Adial Announces Appointment of Tony Goodman as Chief Operating Officer

Dec 20, 2023, 9:00 AM EST - 1 year ago

Adial Pharmaceuticals Receives Final Reimbursement Payment from Adovate

Nov 29, 2023, 4:05 PM EST - 1 year ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirement

Nov 14, 2023, 5:02 PM EST - 1 year ago

Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 31, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss “New Aspects in Substance Use Treatment” at The Annual International Society of Addiction Medicine Conference

Oct 25, 2023, 8:00 AM EDT - 1 year ago

Addiction Experts Highlight the Need for Non-Abstinence-Based Therapies to Treat Alcohol Use Disorder in Adial Pharmaceuticals Key Opinion Leader Webinar

Oct 24, 2023, 4:30 PM EDT - 1 year ago

Adial Pharmaceuticals Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 20, 2023, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 19, 2023, 12:00 PM EDT - 1 year ago

Adial Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference on October 25th

Oct 19, 2023, 10:30 AM EDT - 1 year ago

Adial Pharmaceuticals Awarded Notice of Allowance for Key Patent Combining Use of the Company's Proprietary Genetic Diagnostic with AD04 to Treat Alcohol and Drug Dependence

Oct 18, 2023, 8:00 AM EDT - 1 year ago

Adial Pharmaceuticals Wins Frost & Sullivan's 2023 North American Precision Medicine for Addiction Disorders Technology Innovation Leadership Award

Sep 28, 2023, 7:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Host a Virtual Key Opinion Leader Webinar to Discuss the Unmet Need in Alcohol Use Disorder

Sep 5, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 28, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Chief Medical Officer and Key Opinion Leaders to Discuss the Need for New Alcohol Use Disorder Treatments at the European Society for Biomedical Research on Alcoholism

Aug 23, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements

Aug 21, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 4, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement and Reduce the Public Float

Jul 11, 2023, 8:30 AM EDT - 1 year ago

Adial Provides Business Update Following Favorable Comments from US and EU Regulatory Meetings

Jun 1, 2023, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals to Present at the 2023 Jefferies Global Healthcare Conference on June 9th

May 12, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

May 10, 2023, 8:30 AM EDT - 1 year ago

Adial Pharmaceuticals Receives Notice of Exercise from Adovate for the Acquisition of Purnovate's Assets and Business

Mar 30, 2023, 4:05 PM EDT - 1 year ago

Adial Pharmaceuticals Reports 2022 Fiscal Year Financial Results and Provides Business Update

Mar 21, 2023, 9:00 AM EDT - 1 year ago

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

Mar 8, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals to Present at the 35th Annual Roth Conference on March 14th

Mar 6, 2023, 4:19 PM EST - 2 years ago

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

Mar 2, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Schedules Business Update Conference Call

Feb 27, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Announces Closing of $0.75 Million At-The-Market Registered Direct Offering

Feb 24, 2023, 7:00 AM EST - 2 years ago

Adial Pharmaceuticals Announces Pricing of $0.75 Million At-The-Market Registered Direct Offering

Feb 1, 2023, 9:00 AM EST - 2 years ago

Adial Pharmaceuticals Enters Into Option Agreement for Sale of Purnovate Assets to Adenomed

Nov 14, 2022, 8:30 AM EST - 2 years ago

Adial Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Sep 26, 2022, 9:00 AM EDT - 2 years ago

Market Cap	6.66M
Revenue (ttm)	0.00
Net Income (ttm)	-5.12M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	100,800
Avg Vol	180,506
Day's Range	N/A - N/A
Shares Out	6.41M
Stochastic %K	0%
Beta	1.21
Analysts	Strong Sell
Price Target	$7.67